on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Hosts Successful Boston Radionuclide Theranostics Forum
On May 29, 2025, Eckert & Ziegler held the 3rd annual Boston Radionuclide Theranostics Forum, signifying its prominence in the radiopharmaceutical sector. The event, which attracted about 100 participants, delved into the evolving role of radionuclide theranostics in precision oncology. The forum featured panel discussions and presentations on advancements in radiopharmaceuticals and their supply chain, as well as clinical development challenges. Key industry leaders and experts shared insights on the potential of this technology. The event was fully attended, highlighting the industry's strong interest in radiotheranostics.
Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, emphasized the forum's importance in accelerating progress and enhancing patient access to innovative therapies. The event was organized with the support of sponsors like Solomon Partners and Morrison Foerster, alongside the German American Business Council of Boston. The next edition is scheduled for May 28, 2026, as the company continues to foster global collaboration in the field.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news